BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37988251)

  • 1. The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.
    Buck AM; Deitchman AN; Takahashi S; Lu S; Goldberg SA; Bodansky A; Kung A; Hoh R; Williams MC; Kerbleski M; Maison DP; Deveau TM; Munter SE; Lombardo J; Wrin T; Petropoulos CJ; Durstenfeld MS; Hsue PY; Kelly JD; Greenhouse B; Martin JN; Deeks SG; Peluso MJ; Henrich TJ
    J Med Virol; 2023 Nov; 95(11):e29216. PubMed ID: 37988251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms.
    Buck AM; Deitchman AN; Takahashi S; Lu S; Goldberg SA; Hoh R; Williams MC; Kerbleski M; Deveau TM; Munter SE; Lombardo J; Wrin T; Petropoulos CJ; Durstenfeld MS; Hsue PY; Kelly JD; Greenhouse B; Martin JN; Deeks SG; Peluso MJ; Henrich TJ
    medRxiv; 2023 Mar; ():. PubMed ID: 37034660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females.
    Jansen EB; Ostadgavahi AT; Hewins B; Buchanan R; Thivierge BM; Sganzerla Martinez G; Goncin U; Francis ME; Swan CL; Scruten E; Bell J; Darbellay J; Facciuolo A; Falzarano D; Gerdts V; Fenton ME; Hedlin P; Kelvin DJ; Kelvin AA
    Sci Rep; 2024 Apr; 14(1):9854. PubMed ID: 38684819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.
    Mazzara C; Bassi J; Silacci-Fregni C; Muoio F; Passini N; Corti D; Simonetti GD; Vanoni F; Kottanattu L; Piccoli L
    Eur J Pediatr; 2024 Mar; 183(3):1425-1434. PubMed ID: 38175262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
    Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
    mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron.
    Sieber J; Mayer M; Schmidthaler K; Kopanja S; Camp JV; Popovitsch A; Dwivedi V; Hoz J; Schoof A; Weseslindtner L; Szépfalusi Z; Stiasny K; Aberle JH
    Front Immunol; 2022; 13():882456. PubMed ID: 35663948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Munoz FM; Posavad CM; Richardson BA; Badell ML; Bunge KE; Mulligan MJ; Parameswaran L; Kelly CW; Olson-Chen C; Novak RM; Brady RC; Pasetti MF; Defranco EA; Gerber JS; Shriver MC; Suthar MS; Coler RN; Berube BJ; Kim SH; Piper JM; Miller AM; Cardemil CV; Neuzil KM; Beigi RH;
    Vaccine; 2023 Aug; 41(36):5296-5303. PubMed ID: 37451878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
    Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ
    mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
    Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
    Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Shen X; Hao Y; Wang S; Li D; Ren L; Zhu M; Wang S; Li J; Tang W; Fu Y; Chen R; Liu Y; Shao Y
    Vaccine; 2023 Oct; 41(45):6645-6653. PubMed ID: 37770297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.